Michael Oettel,Prithi S. Kochhar,Hermann Osterwald
申请号：
US14439802
公开号：
US20150283152A1
申请日:
2013.11.04
申请国别(地区):
US
年份:
2015
代理人:
摘要：
Based on specific experimental studies the invention relates to an optimized levonorgestrel-only-composition for improved continuous oral contraception with consequences for suitable pharmaceutical preparations for the same purpose and with defined levonorgestrel content.The invention relates to a pharmaceutical composition for oral contraception for a woman of fertile age consisting of 60 to 100 μg of levonorgestrel and one or more pharmaceutical acceptable carriers and excipients. Furthermore, the invention relates to a pharmaceutical preparation for oral contraception consisting of a number of separately packed and individually removable daily dosage units intended for consecutive daily oral administration, each dosage unit consisting of 60 to 100 μg of levonorgestrel and one or more pharmaceutical acceptable carriers and excipients. Additionally, the invention relates to a dosage regimen, i.e. to the use of an oral dosage form consisting of 60 to 100 μg of levonorgestrel and one or more pharmaceutical acceptable carriers and excipients per dosage unit for oral contraception for a woman of fertile age by administering one dosage unit daily during the complete menstruation cycle.
